A healthcare innovation venture capital firm, CerraCap Ventures, has invested in Acorai, a cardiovascular health technology company. The investment will support the development of Acorai’s Acorai Heart Monitor (AHM), a device designed to measure intracardiac pressures non-invasively, providing accurate and reliable data for heart failure management. With funding from CerraCap Ventures, Acorai plans to conduct global clinical studies to gain FDA approval and launch AHM in the market. This investment reflects CerraCap’s confidence in Acorai’s approach to enhancing patient outcomes and its commitment to transforming cardiovascular health.
CerraCap Ventures Fuels Acorai, Propelling Revolutionary Heart Failure Management
Latest from Blog
Arch Venture Partners secures over $3bn for Fund XIII
TLDR: Arch Venture Partners has raised over $3 billion for Fund XIII. Investors in the fund include Alaska Permanent Fund and Rockefeller Brothers Fund. In a recent development, Arch Venture Partners has
Raising Your First Venture Fund: Tips for Success
TLDR: Samir Kaji, a seasoned venture capital professional, shares a six-point plan for raising a venture fund as a first-time fund manager. Key steps include staying focused on a niche, not worrying
Exploring China’s Quantum Computing Breakthrough and VC Trends
TLDR: ONCO stock surged over 80% in pre-market after Altos Venture acquired a stake Chinese low float stocks like DUO rose over 40% in sympathy with large caps Summary: The article discusses
The Blindspot: Venture Capitalists’ Go-To Tool with Fatal Flaw
TLDR: Nader Al-Naji, founder of Bitclout, was arrested for an alleged crypto scam involving VC giant Andreessen Horowitz as a victim. VCs’ pattern matching led them to invest in Al-Naji despite red
Korean startups seek corporate investors in challenging ecosystem climate
TLDR: Korean startups are seeking corporate investors as funding becomes harder to secure. The government in South Korea has relaxed CVC rules to attract more foreign investment. Korean startups are facing a
